Want to see JP:4598 full AI Analyst Report?
4598 Stock Chart & Stats
¥106.00
-¥3.00(-2.88%)
At close: 4:00 PM EDT
¥106.00
-¥3.00(-2.88%)
Day’s Range― - ―
52-Week Range¥92.00 - ¥700.00
Previous CloseN/A
Volume217.10K
Average Volume (3M)2.24M
Market Cap
¥2.19B
Enterprise Value¥1.72K
Total Cash (Recent Filing)¥83.33M
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-135.25
Shares Outstanding19,235,000
10 Day Avg. Volume316,160
30 Day Avg. Volume2,235,023
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)66.43
Price to Sales (P/S)0.00
P/FCF Ratio-1.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of debt limits interest obligations and refinancing exposure, giving the company a cleaner capital structure than a leveraged biotech. This provides some financial flexibility, although persistent losses and cash burn still create substantial funding pressure.
Prior Revenue BaseThe company has previously demonstrated an ability to generate meaningful revenue, indicating that its business has had commercial activity rather than being entirely pre-revenue. Rebuilding that base could support future sustainability, though recent periods show no revenue.
Reported EPS GrowthThe reported positive EPS-growth metric is a constructive indicator within the available fundamentals and may reflect improvement in per-share results. However, it must be viewed cautiously because the company continues to report large net losses and has not restored revenue.
Bears Say
Sustained Revenue FailureSeveral consecutive fiscal years with zero revenue show that the company currently lacks recurring commercial sales to support operations. Without a demonstrated revenue stream, ongoing development and corporate costs remain dependent on external funding and successful future commercialization.
Persistent And Worsening LossesLarge losses that have worsened over time indicate that the existing operating model is not yet economically self-sustaining. Continued negative profitability can consume remaining resources, weaken financing options, and make future growth dependent on achieving materially better operating results.
Severe Cash Burn And Capital ErosionPersistent cash outflows combined with a sharply reduced equity cushion materially increase funding dependence. Even without debt, the shrinking balance-sheet base leaves less capacity to absorb continued losses or finance development, making capital access important to business continuity.
Delta-Fly Pharma, Inc. News
4598 FAQ
What was Delta-Fly Pharma, Inc.’s price range in the past 12 months?
Delta-Fly Pharma, Inc. lowest stock price was ¥92.00 and its highest was ¥700.00 in the past 12 months.
What is Delta-Fly Pharma, Inc.’s market cap?
Delta-Fly Pharma, Inc.’s market cap is ¥2.19B.
When is Delta-Fly Pharma, Inc.’s upcoming earnings report date?
Delta-Fly Pharma, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 46 days.
How were Delta-Fly Pharma, Inc.’s earnings last quarter?
Delta-Fly Pharma, Inc. released its earnings results on Aug 07, 2026. The company reported -¥30.23 earnings per share for the quarter.
Is Delta-Fly Pharma, Inc. overvalued?
According to Wall Street analysts Delta-Fly Pharma, Inc.’s price is currently Overvalued.
Does Delta-Fly Pharma, Inc. pay dividends?
Delta-Fly Pharma, Inc. does not currently pay dividends.
What is Delta-Fly Pharma, Inc.’s EPS estimate?
Delta-Fly Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Delta-Fly Pharma, Inc. have?
Delta-Fly Pharma, Inc. has 19,235,000 shares outstanding.
What happened to Delta-Fly Pharma, Inc.’s price movement after its last earnings report?
Delta-Fly Pharma, Inc. reported an EPS of -¥30.23 in its last earnings report. Following the earnings report the stock price went down -0.926%.
Which hedge fund is a major shareholder of Delta-Fly Pharma, Inc.?
Currently, no hedge funds are holding shares in JP:4598
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Delta-Fly Pharma, Inc.
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.